September 21, 2017 / 10:00 PM / a month ago

Versartis growth hormone drug fails key study, shares sink

(Reuters) - Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent.

The drug, somavaratan, is a long-acting recombinant human growth hormone.

The company said patients receiving somavaratan failed to show non-inferiority, compared with patients on Pfizer Inc’s drug, Genotropin.

Versartis’ stock, which closed at $21.60 on Thursday, were down at $3.70 in after-hours trading.

Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Maju Samuel

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below